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Abstract  
 
Little is known about frequency, association with clinical characteristics, and 
prognostic impact of DNA copy number alterations (CNA) on survival in central 
primitive neuroectodermal tumors (CNS-PNET) and tumors of the pineal region. 
Searches of MEDLINE, Pubmed, and EMBASE - after the original description of 
comparative genomic hybridization and July 2010 - identified 15 case series of 
patients with CNS-PNET and tumors of the pineal region whose tumors were 
investigated for genome-wide CNA. One additional case study was identified from 
contact with experts. Individual patient data were extracted from publications or 
obtained from investigators, and CNAs were converted to a digitized format suitable 
for data mining and subgroup identification. Summary profiles for genomic 
imbalances were generated from case specific data. Overall survival (OS) was 
estimated using Kaplan-Meier method, by univariable, and multivariable Cox 
regression models. In their overall CNA profiles, low grade tumors of the pineal 
region clearly diverged from CNS-PNET and pineoblastoma. At a median follow-up 
of 89 months, 7-year OS rates of CNS-PNET, pineoblastoma, and low grade tumors 
of the pineal region were 22.9% ± 6%, 0% ± 0%, and 87.5% ± 12%, respectively. 
Multivariable analysis revealed that histology (CNS-PNET),  age  (≤  2.5  years),  and  
possibly recurrent CNAs were associated with unfavorable OS. DNA copy number 
profiling suggests a close relation between CNS-PNET and pineoblastoma. Low 
grade tumors of the pineal region differed from CNS-PNET and pineoblastoma. Due 
to their high biological and clinical variability, a coordinated prospective validation in 
future studies is necessary to establish robust risk factors.  
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Introduction 
 
Central nervous system primitive neuroectodermal tumors (CNS-PNET) are a 
heterogeneous group of WHO grade IV lesions (Supplementary Table 1). They 
comprise 3-7 % of brain tumors in children and young adults [1-2] and are associated 
with a dismal prognosis [3-4]. Histologically, these highly proliferative lesions are 
currently divided into CNS-PNET or supratentorial PNET, respectively (synonym 
PNET not otherwise specified, PNET NOS), CNS neuroblastoma, CNS 
ganglioneuroblastoma, medulloepithelioma, and ependymoblastoma [5]. CNS-PNET 
and medulloblastoma share a similar histology and are often solely distinguishable by 
their supratentorial versus infratentorial location. Further, pineoblastoma, a WHO 
grade IV tumor of the pineal gland [5], is filed in some studies as CNS-PNET 
although pineoblastoma forms a group of neoplasms of the pineal region together with 
pineocytoma, pineal parenchymal tumor of intermediate differentiation, and papillary 
tumor of the pineal region [5]. The classification of malignancies within the group of 
embryonal tumors has changed considerably in the last four editions of the WHO 
classification of tumors of the CNS (Supplementary Table 1). Tumor classification 
systems are increasingly complemented by molecular genetic profiling data, 
especially in hematologic neoplasias [6]. However, for the various subtypes of CNS-
PNET such data is still scarce and large series are missing. Profiling of regional copy 
number abnormalities (CNA) by genomic hybridization techniques is a robust 
methodology for whole genome data analysis. Principle techniques include the 
different variants of chromosomal and array based comparative genomic 
hybridization (cCGH/aCGH; [7-10]) and single-color oligonucleotide array 
technologies (e.g. genomic single nucleotide polymorphism (SNP) arrays).  
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In contrast to data from gene expression measurements, CGH data is easily adaptable 
across multiple datasets to perform a meta-analysis. Methods to assess genomic CNAs 
are standardized and reproducible as demonstrated in previous reports (e.g. [11-12]). 
Some earlier reviews have reported on specific types of aberrations or were focused 
on the descriptive analysis of certain classes of malignancies [13-14]. 
Due to the low incidence of CNS-PNET and pineoblastoma, only a few CGH studies 
have been reported in these tumors [2, 15-17]. So far, results have suggested that 
CNS-PNET are genetically heterogeneous with frequent and diverse CNAs and that 
CNA patterns are distinct from those observed in medulloblastoma [2, 15-17].   
For the present study, we performed an individual patient data (IPD) meta-analysis - a 
specific method of systematic review [18] offering advantages for meta-analysis [19-
20] - of genomic imbalances in CNS-PNET and tumors of the pineal region. The 
collected  data  is  made  available  through  the  “Progenetix”  molecular-cytogenetic 
database (www.progenetix.org: [14, 21-22]).  
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Methods 
 
Search strategy, and selection criteria  
We did a modification of the Cochrane Highly Sensitive Search Strategy for 
prognostic studies [20] combined with predefined search terms in MEDLINE, 
Pubmed, and EMBASE without language restriction [23-24]. The process of the study 
retrieval, in- and exclusion of studies/patients is displayed in the flow chart (Fig. 1) 
according to the PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) statement. The search was limited to articles published after the 
original description of CGH [7] until  July  2010.  Key  words  were:  “medullo(-
)blastoma(s)”,  “primitive  neuroectodermal  tumo(u)r(s)”,  "neuroectodermal  
tumo(u)r(s)  primitive"  “pnet(s)”,  “medullo(-)epithelioma(s)”,  
“ependymoblastoma(s)”,  “ganglioneuroblastoma(s)”,  “pinealoma”,  “pineocytoma(s)”,  
“pineoblastoma(s)”,  “pineal  tumo(u)r(s)”,  “pineal  parenchymal  tumo(u)r(s)”,  “mixed  
transitional  pineal  tumo(u)r(s)”,  “mixed  transitional  pineal  tumo(u)r(s)”,  “atypical  
teratoid rhabdoid tumo(u)r(s)”,  “rhabdoid  tumo(u)r(s)”,  “AT(/)RT”  and  “rhabdoid”,  
“supratentorial  neoplasm(s)”  or  “neuroblastoma(s)”  and  “central  nervous  system  
neoplasm(s)”;;    and  “cgh”  or  “comparative  genomic  hybridization”  or  “snp”  or  “single  
nucleotide  polymorphism”  or  “genomic  array(s)”  or  “copy  number”  or  “dna  
microarray(s)”  or  “amplification”.  Additionally  to  the  search  queries,  we  followed  
references from the selected articles and assessed each abstract. Minimal requirements 
for inclusion of a patient to the study were the availability of case specific genomic 
copy number data with whole genome coverage, the unambiguous diagnostic 
classification of CNS-PNET/tumor of the pineal region, and matching available or 
inferred locus information.  
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Clinical and CNA data collection, data extraction, quality assessment, conversion 
of CNA data, and data synthesis 
For CGH results specified in cytogenetic annotation formats, data was standardized to 
ISCN 1995 (International System for Human Cytogenetic Nomenclature (1995)) “rev  
ish”  format  based on an 862 bands karyotype and checked for semantically correct 
annotation using dedicated software. For genomic array data without annotated 
gain/loss information, clone specific data files were segmented using Progenetix 
website tools. Normalized data was converted to Golden Path mapped copy number 
status information by software implemented in the Perl scripting language [14].  
In a first step, clinical and genomic data were extracted from publications by two 
reviewers (AOVB and MB). Subsequently, the original data, in particular in case of 
incomplete data (genomic and clinical data), for each participant was obtained and 
updated directly from the researcher responsible for each included study [25]. To 
prevent duplicate inclusions, authors were asked to indicate whether a patient had 
been analyzed within different studies. In addition, copy number profiles were 
clustered for similarity and reviewed for the occurrence of profile pairs, in order to 
avoid duplicate cases due to republished data. Data of 3 unpublished CNS-PNET 
patients were provided by two authors (SP and OD). Generally, two approaches to 
perform IPD meta-analyses are used. First, IPD meta-analyses can be performed 
directly, as if all  data  belong  to  a  single  trial/study,  termed  the  “one-stage”  approach  
[26].  Second,  a  “two-stage”  approach  can  be  also  used.  Each  trial/study is analyzed 
separately using its raw data before the summary results from each trial/study are 
pooled and analyzed using conventional meta-analyses techniques [26]. Due to the 
small  patient  numbers  of  each  individual  case  series  the  “one-stage”  approach  was  
used here.  
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Exploratory data mining and statistical analysis   
For the evaluation of regional copy number changes, non-overlapping genomic 
segments were generated based on the complete CNA data from all cases. For each of 
these intervals, case specific involvement was evaluated and gain/loss frequencies 
determined. For visualization and ordering of case specific CNA data, data matrices 
were produced containing imbalance status (gain, or loss) mapped to a variety of 
genomic intervals (from chromosomal arm level down to 1Mb). Cases were ordered 
by hierarchical clustering of gain/loss matrices (unsupervised, complete linkage), and 
the derived case order was used for re-plotting of the original CNA annotations. A 
relatively resolution-independent surrogate marker of genomic instability, CNA 
complexity, was determined for each case by evaluating the occurrence of gain and 
loss events per chromosome arm, with a maximum score of 2 per arm (i.e. occurrence 
of one or more of each gain and loss; modified from [27]). 
To evaluate imbalance distribution in relation to diagnostic assignment, for each of 
the entities in our dataset gain/loss frequencies were calculated mapped to genomic 
intervals on a 5Mb level. Copy number profiles were compared by generating a 
heatmap of gain/loss distributions. 
Cases with clinical follow-up were evaluated with respect to correlation of clinical 
factors and regional CNA status to OS. OS was defined as date of diagnosis to death 
of any cause or to the date of last visit. Cut-off values of age and CNA complexity 
were determined by recursive partitioning [28]. Univariable and multivariable 
survival analyses were performed. OS was estimated by the Kaplan-Meier method, 
and the log-rank test was used for comparisons of survival in different groups [29]. 
Univariable analyses to investigate the effect of age (continuous), and CNA 
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complexity (continuous) on OS was done with univariable Cox regression analysis. 
Multivariable  analyses  were  performed  using  Cox’s  proportional hazards model. All 
statistical analyses are intended to be rather exploratory than confirmatory. P-values 
are considered statistically significant in case p < 0.05. No adjustment for multiple 
testing was carried out. Statistical analyses were performed using SAS (Version 9.2 
for Windows, SAS Institute Inc., Cary, NC, USA), and PASW Statistics 18 for 
Windows (SPSS Inc., Chicago, IL, USA). 
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Results  
 
Figure 1 illustrates the process of evaluating articles for inclusion in the IPD meta-
analysis. We identified 1220 papers by the search terms. The number of papers was 
reduced to 840 after removing of duplicates (by titles and abstracts). Title and abstract 
review resulted in the exclusion of 710 papers. Three case specific data (one case 
series) were provided by two authors. We reviewed 131 papers in full, from which 15 
studies, and one unpublished case series (n=3), met inclusion criteria for this study 
(Supplementary Figure 1).  
 
Study characteristics and quality assessment 
The 16 studies included here comprised 107 patients in total, after exclusion of 4 
cases with ambiguous CNA profiles. From 61 patients information about OS was 
available (clinical characteristics are shown in Table 1). Of those, 38 patients were 
profiled using aCGH and 23 patients using cCGH. The median follow-up time for 
survivors was 75 months, and the median follow-up time across all patients was 89 
months.  Fifteen  children  were  aged  ≤  2.5  years,  46  patients  were  aged  >  2.5  years.  
The cohort compromised all tumor entities classified as CNS-PNET in the current 
WHO classification when taking into account the update of earlier WHO 
classification in which some of these tumors were partly classified as different 
subgroups of embryonal tumors [5, 30]  (n=46), and tumors of the pineal region 
(n=15) which included pineocytoma (n=4), pineal parenchymal tumor of intermediate 
differentiation (n=3), papillary tumor of the pineal region (n=5), and pineoblastoma 
(n=3).  Mean CNA complexity was 9.4 (range, 0.00-30.00). For the purpose of 
statistical analysis, CNS-PNET were considered as one group and tumors of the 
pineal region were considered as another group.  
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Overall genomic imbalance patterns in central nervous system primitive 
neuroectotermal tumors and tumors of the pineal region  
In order to evaluate the overall patterns of genomic imbalances in bona fide CNS-
PNET and tumors of the pineal region, we visualized the case-specific CNAs of all 
tumors clustered for their overall imbalance similarities (Fig. 1 a). In CNS-PNET 
(n=88), frequent gains of chromosomes 1q4 (n= 31 [35%]), 2p2 (n= 27 [31%]), and 
7q3 (n= 16 [18%]) as well as losses involving chromosome 13q2 (n= 21 [24%]), and 
6q (n= 18 [20%]) could be observed among other less frequent changes (Fig. 1 b). In 
contrast, low grade tumors of the pineal region were characterized by gains of 
chromosomes 4q2 (n= 6 [46%]), and 12 (n=5 [38%]) as well as losses of 
chromosomes 10 (n=4 [31%]), and 22 (n=5 [38%]). Interestingly, pineoblastoma 
(n=6) displayed a pattern of genomic imbalances unrelated to the changes observed in 
the group of low grade tumors of the pineal region. Supplementary Figures 2-4 
illustrate gains and losses of the different disease entities.  
We observed frequent gains involving chromosome 2 and losses involving 
chromosome 6 in ependymoblastoma as well as in medulloepithelioma 
(Supplementary Fig. 3b, 3c). Losses of chromosome 6 and 13 were typical for 
ependymoblastoma.  
Embryonal tumor with abundant neuropil and true rosettes (ETANTR) was first 
described by Eberhart et al. [31], but is so far not listed as a distinct tumor entity in 
the 2007 WHO classification [5] and represents a CNS-PNET with 
“ependymoblastic”  rosettes  [32]. Recently, Korshunov and colleagues demonstrated 
in a series of 21 ependymoblastoma and 20 ETANTR that 95% of ETANTRs and 
90% of ependymoblastoma have the unique focal amplification at 19q13.42 [33].  
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Therefore, the term embryonal tumor with multilayered rosettes (ETMR) has been 
suggested for ependymoblastoma and ETANTR, a new entity with multilayered 
rosettes for which amplification at 19q13.42 represents a rather sensitive and specific 
marker [32].  
In our cohort we identified 9 tumors with such an amplification (one ETANTR 
reported by Pfister et al. [33]; all other tumors reported by Li et al. [2]). As described 
previously by Li et al. [2], cases with such an amplification predominantly (8/9) also 
displayed gains of the whole or the major part of chromosome 2. For some additional 
cases with gain of chromosome 2 identified by cCGH, no high resolution data was 
available. Therefore, we may not role out an additional amplification at 19q13.42 in 
these cases. 
 
Univariable and multivariable survival analysis of clinical factors and CNA 
complexity  
To assess which parameters contribute to prognosis, we evaluated each clinical 
variable by univariable Kaplan-Meier analysis. Tested variables were: Gender, age, 
histology, (CNS-PNET versus tumors of the pineal region), metastatic stage (no 
metastases versus metastases), extent of postoperative residual disease 
(complete/gross total resection versus residual disease  ≥  1.5  cm2), radiotherapy (no 
radiotherapy/local radiotherapy versus cranio-spinal radiotherapy), chemotherapy (no 
chemotherapy  versus  chemotherapy),  CNA  complexity  (<  11  versus  ≥  11  as  defined  
by recursive partitioning), tumor sample source (primary tumor versus relapse), and 
technique (aCGH versus cCGH). Supplementary Table 2 illustrates the factors 
(histology, CNA complexity, and age) showing differences as assessed by univariable 
analysis. Patients with tumors of the pineal region had a more favorable OS when 
compared to patients with CNS-PNET (7-year OS: 64.7% ± 15% versus 22.9% ± 6%, 
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p=0.007). Of note, all three patients with a pineoblastoma and available follow-up 
were dead 33 months after diagnosis, whereas all other patients with low grade tumors 
of the pineal region had excellent outcome (7-year OS: 87.5% ± 12%). Patients aged 
≤  2.5  years  had  unfavorable  OS  when  compared  to  patients  aged  >  2.5  years  (7-year 
OS: 0% ± 0% versus 41.3% ± 8%, p=0.001). OS rates were similar in CNS-PNET 
patients with and without the amplification at 19q13.42. Univariable cox regression 
analysis confirmed that increasing age (continuous variable) is denoting a more 
favorable OS (hazard ratio, 0.967 [per year]; 95% confidence interval, 0.939-0.996; P 
= 0.0282) and increasing CNA complexity (continuous variable) a less favorable OS 
(hazard ratio, 1.063 [per unit]; 95% confidence interval, 1.012-1.117; P = 0.0153). 
Multivariable analysis of clinical factors and CNA complexity revealed that histology 
(tumors of the pineal region), age (older than 2.5 years) and CNA complexity < 11 are 
favorable prognostic factors (Table 2).  
 
Multivariable survival analysis of chromosomal aberrations, CNA complexity, 
and clinical factors 
To identify which of the chromosomal aberrations might have an impact on OS, multivariable 
survival analyses were applied to all 61 patients incorporating the significant clinical factors 
(histology, and age), CNA complexity, as well as 75 different chromosomal gains and 75 
different chromosomal losses in a stepwise approach, respectively. These analyses finally 
revealed  that  young  age  (≤  2.5  years),  histology  (CNS-PNET), and recurrent gains of 3p1 
(n=3; 5%), 13q1 (n=5; 8.2%), and 15q2 (n=8; 13.1%) are associated with an increased risk for 
unfavorable OS (Table 3). 
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Discussion  
 
Over the last years, whole genome/transcriptome molecular analysis has led to the 
identification of divergent biological characteristics in what were considered single 
cancer types. In the field of pediatric neuro-oncology, medulloblastoma are now 
considered as a group of biologically differing entities consisting of at least 4 
molecular subgroups, loosely connected through their topography (cerebellum) and 
partially overlapping histological appearance [34-42].  
Molecular studies in rare tumor entities are severely limited due to the low number of 
cases included in single series, as well as conceptual and technical heterogeneity of 
the studies. To our knowledge, our study is the first IPD meta-analysis assessing the 
genomic and clinical features in CNS-PNET and tumors of the pineal region and their 
impact on OS. In this study, we show that CNS-PNET and pineoblastoma are 
divergent in their CNA profiles when compared with low grade tumors of the pineal 
region. For the cases analyzed here, recurring CNA observed only in low grade 
tumors of the pineal region were e.g. gains on 4q2, 9p, 12p, and 8q2 as well as 
deletions of chromosome 10. In contrast, recurring CNA only found in pineoblastoma 
were deletions on 4q, chromosome 9, and 1p3. Based on our results, CGH analysis 
might be of help - in addition to neuroradiological and histopathological evaluation – 
to differentiate between CNS-PNET, pineoblastoma, and lower WHO grade tumors of 
the pineal region. While detection of the listed aberrations may be indicative for 
assignment to one of the diagnostic groups, development of a CNA-based classifier 
will ideally require larger numbers of genome profiles.  
We found evidence that younger age at time of diagnosis is a negative prognostic 
factor for OS, confirming several previous studies reporting on poor outcome of 
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young children with CNS-PNET/pineoblastoma [3, 43]. Timmermann and colleagues 
report on OS and progression-free survival rates after 3 years of 17.2% and 14.9%, 
respectively [3]. Administration of radiotherapy was the only significant prognostic 
marker (15 out of 29 patients were not irradiated) in this study [3] suggesting that 
omitting the radiotherapy in young children – with the goal to reduce neurologic 
sequelae – might at least explain partly the extremely poor outcome of young children 
with CNS-PNET/pineoblastoma.  
In our cohorts, CNS-PNET and pineoblastoma shared an unfavorable prognosis. 
Small numbers of pineoblastoma (3 out of 61 patients) may limit the comparison of 
those two tumor entities. Based on the literature, there is some evidence that patients 
with pineoblastoma may do better than patients with CNS-PNET [44-45]. Patients 
with low grade tumors of the pineal region had a favorable outcome (7-year OS: 
87.5% ± 12%) confirming that those tumor entities need a less aggressive treatment 
than CNS-PNET/pineoblastoma.  
CNS-PNET and tumors of the pineal region share a complex karyotype with frequent 
CNAs [46]. In our series of 107 patients, low grade tumors of the pineal region 
showed relative frequently absence of CNAs (4/13), less frequently in pineoblastoma 
(1/6), and CNS-PNET (2/88).   
Recently, a new entity of CNS-PNET termed ETMR has been suggested for a 
subgroup of CNS-PNET (ependymoblastoma and ETANTR) for which amplification 
at 19q13.42 represents a rather sensitive and specific marker [32]. Korshunov et al. 
[33] identified in the great majority of ependymoblastoma and ETANTR the focal 
amplification at 19q13.42 whereas such an amplification was not observed in a large 
series of other pediatric brain tumors [32]. As we report about cCGH and aCGH data, 
the frequency of tumors with amplification at 19q13.42 (Supplementary Fig. 6) 
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should be interpreted with caution as detection of the amplification at 19q13.42 might 
be missed when tumors are profiled by conventional cCGH which has a spatial 
resolution limited of several megabases. Patients with 19q13.42 amplified tumors had 
a relatively poor OS (6/7 patients with available follow-up died of disease). Of note, 
the analysis of the prognostic impact of the amplification at 19q13.42 is limited in our 
cohort, because – as mentioned above – this amplification might be missed in tumors 
analyzed with cCGH.  
Our results provide evidence that high CNA complexity is an unfavorable prognostic 
marker in our cohort. Because of high frequencies of genomic imbalances as well as 
heterogeneous patterns and frequencies of CNAs, CNA complexity appears to be a 
good measure for overall genomic instability which may reflect aggressiveness of a 
certain tumor. In light of this, specific recurrent genomic imbalances which have been 
identified as CNAs with potential impact on OS in our analyses (e.g. in the 61 
patients: gain of seg3p1 (n=3), seg13q3 (n=5), seg15q2 (n=8)), need to be validated – 
ideally in large future studies - for their prognostic value.  
After the search cut-off date imposed by the IPD meta-analysis criteria, another study 
was published recently focusing on CNS-PNET/pineoblastoma only in pediatric 
patients [17]. By evaluating the genomic array data which are available from  NCBI’s  
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/; accession number 
GSE12370), we were able to generate CNA profiles for 38 patients (8 of whom had 
pineoblastoma, and 30 had a CNS-PNET; CGH data from 35 CNS-PNET cases were 
listed, 5 recurrent tumors were paired with a primary sample from the same patient) 
and 1 CNS PNET cell line. Here, as in our IPD meta-analysis, pineoblastoma 
exhibited CNA profiles roughly comparable to subsets of cases identified as CNS-
PNET as shown in the Supplementary Figure 5 a, b.  
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The approach of an IPD meta-analysis – a specific method of systematic review based 
on a systematic search - is in our opinion both necessary and efficient to increase the 
patient number in rare tumor diseases. By using IPD we may overcome many of the 
limitations of systematic reviews (e.g. poor quality of data can be improved by 
updating the information). We used common inclusion and exclusion criteria for each 
individual case. In addition, we have performed a quality assessment of genomic data 
by reassessment of each individual case by two researchers (MB and HC). Methods to 
assess genomic CNAs are standardized and reproducible as demonstrated in previous 
reports (e.g. [11-12]). Moreover, by including unpublished data [25], we aimed to 
reduce the risk for publication bias [20]. Of course, the inclusion of a larger number 
of  unpublished  cases  would  have  been  desirable  and  a  “pooling”  of  such  data  has  an 
exceptional value for rare diseases. Of note, IPD meta-analyses usually takes longer 
than conventional systematic review, and obtaining IPD is time-consuming [20]. 
Therefore, it is not possible to include all very recent studies, and many IPD meta-
analyses are conducted on a cyclical basis with data collection, quality assessment, 
analyses and dissemination of results taking place every few years [18], because by 
the time of the final analysis of the pooled data already new cases are available. We 
acknowledge some limitations of our study which is based on original data produced 
over a time period of several years. As shown in Supplementary Table 1, the WHO 
classification of tumors of the CNS has changed during this period. Moreover, in the 
recent years the staging has improved, as have surgical procedures and non-surgical 
treatment options of patients with CNS-PNET and tumors of the pineal region. 
Regarding genomic analysis methods, high-resolution profiling by genomic copy 
number arrays or whole genome sequencing could provide a higher sensitivity for the 
detection of hitherto undetected CNA. However, the main limitations in identifying 
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robust CNA markers with prognostic value are in the limited number of samples and 
associated clinical datasets available for such analyses.  
In summary, CNS-PNET and low grade tumors of the pineal region are characterized 
by differences in CNA profiles. In this respect, pineoblastoma fit readily into the 
genomically heterogeneous group of CNS-PNET with a complex karyotype. Although 
not necessarily displayed by each individual case, typical CNA profiles underline the 
differing biological background of these entities. Our results provide evidence that 
young age, high CNA complexity, and potentially also several specific CNAs may 
have an impact on OS.  
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Figure legends 
 
Fig. 1   Delineation of 3 distinct clinicogenetic subgroups 
a Regional copy number imbalances for individual cases were plotted separately by 
overall diagnostic assignment (yellow: gain; blue: loss; blue: tumors of the pineal 
region except pineoblastoma; light blue: pineoblastoma; pink: central primitive 
neuroectodermal tumors (CNS-PNET)). Individual profiles were arranged by 
hierarchical clustering inside their groups. b Histograms of genomic gain and loss 
frequencies (color legend corresponding to (a)).  
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Tables 
Table 1   Demographics and disease characteristics of 61 patients with 
Central Primitive Neuroectodermal Tumors (CNS-PNET) and Tumors of the 
Pineal Region 
Characteristics Number of patients   (complete 
follow-up; n=61) 
Sex  
Male 21 (21%) 
Female 17 (28%) 
N/A 31 (51%) 
Age  
Median age at diagnosis (range; years) 4.2 (0.6-66) 
Histology  
CNS-PNET 46 (75%) 
Tumors of the pineal region 15 (25%) 
Tumor samples source  
Primary tumors 59 (97%) 
Relapses 2 (4%) 
Metastatic stage  
Metastases 8 (13%) 
No metastases 21 (35%) 
N/A 32 (52%) 
 
N/A, information not available 
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Table 2   Multivariable analyses of clinical prognostic factors (n=61) for 
overall survival (OS) 
 
Parameter Comparison Sample size HR OS  95% Confidence interval (CI) p-value  
Histology 
Non CNS-PNET  15 
0.312 0.109-0.891 0.0296 
CNS-PNET 46 
Age group (years) 
> 2.5 46 
0.386 0.197-0.757 0.0056 
≤  2.5 15 
CNA complexity 
≥  11  CNA 23 
1.790 0.943-3.400 0.0752 
< 11 CNA 38 
 
CNS-PNET, Central primitive neuroectodermal tumor; Non CNS-PNET, tumors of 
the pineal region; CNA, copy number aberrations; HR OS, Hazard ratio overall 
survival 
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Table 3  Multivariable analyses of clinical factors and recurrent 
chromosomal aberrations (forward stepwise selection; n=61) for overall survival 
(OS) 
 
Parameter sample size Hazard ratio 
overall survival 
(OS) 
95% Confidence 
interval (CI) 
p-value 
Age  (≥  2.5  years) 46 0.295 0.141-0.619 0.0012 
Histology (tumor of the pineal 
region) 
15 0.120 0.029-0.498 0.0048 
seg3p1_gain 3 8.759 1.778-43.159 0.0077 
seg13q3_gain 5 4.128 1.192-14.303 0.0253 
seg15q2_gain 8 4.338 1.614-11.665 0.0036 
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Supplementary Table 1   WHO Classification of Tumors of the Nervous 
System 1993-2007: Embryonal Tumors 
 
WHO 1993 WHO 1997 WHO 2000 WHO 2007 
Medulloblastoma 
Medullomyoblastoma 
Melanotic MB 
Desmoplastic MB 
Medulloblastoma 
Medullomyoblastoma 
Melanotic MB 
Desmoplastic MB 
MB with extensive 
nodularity 
Large cell MB 
Lipomatous MB 
Medulloblastoma 
Medullomyoblastoma 
Melanotic MB 
Desmoplastic MB 
MB with extensive 
nodularity 
Large cell MB 
 
Medulloblastoma 
Desmoplastic / nodular 
MB 
MB with extensive 
nodularity 
Large cell MB 
Anaplastic MB 
Primitive 
neuroectoderma tumor 
(PNET) 
Supratentorial PNET 
(sPNET) 
Supratentorial PNET 
(sPNET) 
Neuroblastoma 
Ganglio-neuroblastoma 
CNS-PNET 
CNS Neuroblastoma 
CNS Ganglio-
neuroblastoma 
Medulloepithelioma 
Ependymoblastoma 
Neuroblastoma 
Ganglio-neuroblastoma 
Central neuroblastoma 
Ganglio-neuroblastoma 
  
Medulloepithelioma Medulloepithelioma Medulloepithelioma  
Ependymoblastoma Ependymoblastoma Ependymoblastoma  
 Atypical 
teratoid/rhabdoid tumor 
Atypical 
teratoid/rhabdoid tumor 
Atypical 
teratoid/rhabdoid tumor 
 
MB, medulloblastoma; CNS, Central nervous system; PNET, primitive 
neuroectodermal tumor 
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Supplementary Table 2: Overall survival (OS) according to clinical factors and 
CNA complexity, univariable analyses on 61 patients 
 
Parameter Comparison Sample size 7-year OS (%) p-value  
Histology 
CNS-PNET  46  22.9 
0.007 
Non CNS-PNET 15 64.7 
Age group 
(years) 
≤  2.5   15 0.0 
0.001 
> 2.5 46 41.3 
CNA complexity 
< 11 CNA 38 39.9 
0.057 
≥  11  CNA 23 19.6 
 
 
 
CNS-PNET, Central primitive neuroectodermal tumor; Non CNS-PNET, tumors of 
the pineal region; CNA, copy number aberrations; OS, overall survival 
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Supplementary Figure legends 
 
Supplementary Fig. 1 Flow chart of study selection process.   
CNS, Central nervous system; PNET, primitive neuroectodermal tumor 
 
Supplementary Fig. 2  Overall imbalance frequencies in 107 tumors of 
different histological classifications (low grade tumors of the pineal region, n=13; 
pineoblastoma, n=6; CNS-PNET, n=88) 
a Histogram: green/up: percent of cases with copy number gain in corresponding 
region; red/down: percent of cases with losses. b Gain/loss profile overview: 
comparison of the normalized gain/loss frequencies for the different entities (i.e. the 
highest value for either gain or loss leads to a maximum color intensity of the 
respective green or red color channel) 
 
Supplementary Fig. 3 International Classification of Diseases (ICD) 
mapped subset profiles for CNS-PNET and pineoblastoma 
a CNS-PNET, NOS tumors (ICD-O 9473/3; 77 cases). b Ependymoblastoma (ICD-O 
9392/3; 9 cases). c Medulloepithelioma (ICD-O 9501/3; 2 cases). d Pineoblastoma 
(ICD-O 9362/3; 6 cases).  
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 - 30 - 
Supplementary Fig. 4  International Classification of Diseases (ICD) 
mapped subset profiles for low grade tumors of the pineal region 
a Papillary tumors of the pineal region (ICD-O 9395/3; 5 cases). b Pineal 
parenchymal tumors of intermediate differentiation (ICD-O 9362/3; 3 cases). c 
Pineocytoma (ICD-O 9361/1; 5 cases) 
 
Supplementary Fig. 5  Comparison dataset (Miller et al. [17], PMID 
21798848)  
a Case specific gain/loss regions sorted for 8 pineoblastoma and 31 CNS-PNET cases 
(one cell line) extracted from PMID 21798848. b Frequency profiles of the case 
groups in Supplementary Figure 4A.  
 
Supplementary Fig. 6  Focal amplification at chromosome 19q 
a Gains (yellow)/losses (blue) in 9 cases with focal amplification at 19q1. 
Remarkably, 8/9 cases also display gains of at least parts of chromosome 2, a feature 
observed also in a subset of other CNS-PNET tumors. b Three example plots of the 
amplified region on chromosome 19q1, generated from data available through the 
GEO deposit GSE14087 (Li et al. [2], PMID 19962671). Of note is the apparently 
complex structure of the region in GSM353483 and GSM353447. 
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)LJXUH
&OLFNKHUHWRGRZQORDGKLJKUHVROXWLRQLPDJH
MEDLINE, PubMed, and EMBASE searched 
from January, 1992, to July, 2010
Potentially relevant studies 
n=1220
Studies included in meta-analysis (n=16, 107 patients (exclusion of 4 cases); 
61 patients with information about overall survival)
Excluded by title and abstract 
review
n=710
After duplicates removed 
n=840
Full copies retrieved and assessed for eligibility 
n=130
Study identified from contact with 
experts 
(3 unpublished CNS-PNET)
Excluded, not eligible 
for this study 
n=115
Studies included in meta-analysis 
(n=15, 104 patients)
YRQ%XHUHQB6XSSOHPHQWDU\)LJXUH
&OLFNKHUHWRGRZQORDG6XSSOHPHQWDO0DWHULDOBBBYRQ%XHUHQB6XSSOHPHQWDU\)LJXUHSSW
Figure S2a
Figure S2b
 
YRQB%XHUHQB6XSSOHPHQWDU\)LJXUHV
&OLFNKHUHWRGRZQORDG6XSSOHPHQWDO0DWHULDOBBBYRQB%XHUHQB6XSSOHPHQWDU\)LJXUHVSGI
Figure S3a
Figure S3b
  
Figure S3c
Figure S3d
Figure S4a
Figure S4b
Figure S4c
Figure S5a
Figure S5b
primitive neuroectodermal
tumors, nos
pineoblastomas
pineoblastomas
immature CNS-PNET 
tumors / "blastomas"
AB
YRQB%XHUHQB6XSSOHPHQWDU\)LJXUH
&OLFNKHUHWRGRZQORDG6XSSOHPHQWDO0DWHULDOBBBYRQB%XHUHQB6XSSOHPHQWDU\)LJXUHSGI
